Search Results

In an interview with touchNEUROLOGY, Prof. Heinz Reichmann (University of Dresden Medical School, Germany) gave us his insight into his highlights in Parkinson’s disease, the interventions currently under investigation and how he sees management strategies for Parkinson’s disease evolving in the coming years. Questions: What are your highlights from the Parkinson’s disease scientific sessions at […]

We were delighted to meet with Heinz Reichmann (Technische Universität Dresden, Dresden, Germany) to discuss the key real world findings from the OPTIPARK study, investigating the use of Opicapone in the treatment of Parkinson’s disease. The abstract entitled: ‘Opicapone in Parkinson’s patients with motor fluctuations and complications of therapy at baseline: the OPTIPARK study’ was presented […]

We were delighted to meet with Heinz Reichmann (Technische Universität Dresden, Dresden, Germany) to discuss the use of levodopa-based drugs for managing Parkinson’s disease. The abstract entitled: ‘Opicapone in Parkinson’s patients with motor fluctuations and complications of therapy at baseline: the OPTIPARK study’ was presented at the 7th Congress of the European Academy of Neurology […]

As always, we were pleased to have the opportunity to catch-up with valued editorial board member Heinz Reichmann (Technische Universität Dresden, Dresden, Germany), who spoke to us on the topic of the lecture he gave during the on-demand sessions entitled: The Gut Microbiome in the Pathogenesis of Parkinson’s Disease. Questions 1. Could you tell us […]

Heinz Reichmann (Universitätsklinikum Carl Gustav Carus, Dresden, Germany) shares key findings and expert insights into the OPTIPARK study, a prospective, open-label, uncontrolled, single-group, multi-centre trial in patients with Parkinson’s disease and wearing-off motor fluctuations (ClinicalTrials.gov Identifier: NCT02847442). Questions 1. What were the aims and design of the OPTIPARK study? (0:05) 2. What were the efficacy […]

We were fortunate to have the opportunity to catch up with European editorial board member, Heinz Reichmann (Universitätsklinikum Carl Gustav Carus, Dresden, Germany), who spoke to us about unmet needs in the treatment of Parkinson’s disease and clinical evidence supporting the efficacy and safety of catechol-O-methyltransferase inhibition as a means to prolong the effects of […]

Following approval in Europe in 2015 and in the USA in 2017,1 and its subsequent introduction, safinamide has become established as an effective and well-tolerated add-on to levodopa treatment in Parkinson’s disease (PD). Despite the extensive clinical trial data and a growing body of real-world experience of this drug,1,2 there are still aspects of its […]

Introduction Safinamide is an innovative therapeutic option in Parkinson’s disease (PD), with a unique dual mode of action that goes beyond dopaminergic pathways.1 Its mechanisms of action include monoamine oxidase-B (MAO-B) and dopamine reuptake inhibition, activity-dependent sodium-channel inhibition, and inhibition of glutamate release.2 In pivotal clinical trials, safinamide used as add-on to levodopa, demonstrated efficacy […]